Emulate is a biotechnology company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Emulate is igniting a new era in human health with industry leading organ-on-a-chip technology.

Emulate was founded in 2014 by Donald Ingber and James Coon. The company is headquartered in Boston, Massachusetts.


Emulate's Human Emulation System provides a window into the inner workings of human biology and disease—offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing.


Emulate's Organ-on-a-chip technology provides flexible microenvironments containing tiny hollow channels lined with living cells and tissues that can be subjected to mechanical forces that mirror breathing or digestion in the human body.


Emulate's technology is used by leading academic researchers, government entities, and many of the largest pharmaceutical companies to better understand the biology of human disease.


Emulate is backed by Northpond Ventures, Founders Fund, Perceptive Advisors, National Institutes of Health, ALS Investment Fund, and others. The company raised $82M in Series E round on Sep 07, 2021. This brings Emulate's total funding to $224.3M to date.



  • Year founded: 2014
  • Funding Info: $224.3M over 8 Rounds (Latest Funding Type: Series E)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: Unknown
  • City/Town: Boston
  • State: Massachusetts
  • Country: United States
Related businesses